Background and Objectives HMG-CoA reductase inhibitors have been used for a decade to lower LDL cholesterol levels and to improve cardiovascular diseases and clinical outcomes. This study was designed to evaluate the clinical efficacy and safety profiles of atorvastatin, a new HMG-CoA reductase inhibitor, in patients with elevated LDL-cholesterolemia. Material and Methods Eighty three patients who had high 12-hour fasting serum LDL-cholesterol level 145 mg dl and 250 mg dl and serum TG level less than 400 mg/dl were enrolled. After completing an 4 week dietary phase, 50 patients who still had LDL-C 145 mg dl and TG 400 mg/dl were assigned to receive atorvastatin 10 mg once daily for 4 weeks. After 4 weeks, the dose was continued for 4 weeks in each individual if serum LDL-cholesterol was maintained below 130 mg dL. For each individual whose serum LDL-cholesterol was above 130 mg dL, the dose was doubled 20 mg day and administered for 4 weeks. Serum AST, ALT and CPK were also measured in addition to blood chemistry tests for lipid profiles at 4 and 8 weeks for safety assessment. Results 1 The total study population who completed the whole protocol was composed of 46 patients 23 male, 23 female, mean age 54 years . 2 At 4 weeks, the reduction by mean percent change from the baseline in LDL-cholesterol was 44.8% from 182.3 3.4 mg dl to 99.7 2.9 mg dl . The fixed goal of LDL-cholesterol less than 130 mg dl was achieved by 95.8%. 3 At 4 weeks, the mean percent change from the baseline in TC, TG, HDL-C, LDL/HDL-C and ApoB were 32.3%, 17.4%, 9.6%, 48.5% and 36.6%, respectively. 4 At 8 weeks, the mean percent change from the baseline in LDL-cholesterol was 43.0% from 182.3 3.4 mg dl to 103 2.4 mg dl . The fixed goal of LDL-cholesterol less than 130 mg/dl was achieved by 91.3% of the whole patients. 5 At 8 weeks, the mean percent change from the baseline in TC, TG, HDL-C, LDL HDL-C and ApoB were 31.3%, 22.6%, 13.7%, 48.8% and
35.9%, respectively. 6 No serious side effects were observed during the whole period. Conclusion Atorvastatin is highly effective and safe in modulating lipid profiles favorably lower LDL-Cholesterol, lower TG, elevate HDL-Cholesterol , in 
유효성 약제의 안전성

